CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 25,003 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00420966
NCT00420966N/ACompleted
CompareCT.gov

Phase IV Study of Respiratory Syncytial Virus Monoclonal Antibody Therapy in High-risk Infants and Toddlers

Sunnybrook Health Sciences Centre·observational·Posted Jan 11, 2007·Updated Apr 17, 2018

In Brief

An observational study for Lower Respiratory Tract Infection and Respiratory Syncytial Virus Infections. Completed, enrolled 25,003 participants across 2 sites.

Detailed Summary

The purpose of this study is to determine the utilization patterns and compliance rates of palivizumab, which is a monoclonal antibody therapy used to prevent respiratory syncytial virus infection.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsLower Respiratory Tract Infection, Respiratory Syncytial Virus Infections
CountriesCanada
CollaboratorsAbbott

Timeline

N/ACompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 11, 2007
Enrollment StartOct 1, 2005
Primary CompletionJun 26, 2017
TodayJul 2, 2026
Enrollment to primary: 11.7 yearsPosted 19.5 years ago